Business Context and Reporting Period
This Form 8-K Current Report for Indaptus Therapeutics, Inc. (INDP) covers events occurring on March 18, 2026, and a transaction closing on March 23, 2026. The filing details a significant change in control involving the sale of preferred stock by a major shareholder to a new group of investors, accompanied by a complete restructuring of the Board of Directors and executive leadership.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data relates to a private equity transaction:
- Total Purchase Price: $11,200,000 paid by a group of five purchasers (Yun Yao, SinoLion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng).
- Assets Acquired: 700,000 shares of Series AAA Convertible Preferred Stock and 196,800 shares of Series AA Convertible Preferred Stock previously held by David E. Lazar.
- Conversion Potential: The acquired preferred stock converts into 108,936,000 shares of Common Stock.
- Post-Transaction Ownership: Assuming full conversion, the new group will beneficially own approximately 96.20% of the company's outstanding Common Stock.
Material Changes Versus Prior Period
The filing reports a fundamental shift in corporate control and governance compared to the prior period:
- Change in Control: David E. Lazar sold the majority of his preferred stock holdings, reducing his potential ownership to approximately 1.82% post-conversion.
- Board Resignations: Four directors (Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes) resigned effective March 18, 2026.
- Executive Departures: Jeffrey A. Meckler and David Lazar resigned as co-Chief Executive Officers. David Lazar also stepped down as Chairman of the Board but remains a director.
- New Leadership: Junyi Dai was appointed Chairman of the Board and Chief Executive Officer.
Guidance, Outlook, and Management Commentary
The filing does not contain financial guidance, revenue outlook, or management commentary regarding future business operations or clinical milestones. Key governance and risk-related items include:
- Joint Filing: The new purchasers intend to file a joint Schedule 13D, indicating they may be deemed a "group" under Section 13(d)(3) of the Exchange Act.
- Registration Rights: The Company agreed to include 2,064,000 shares of Common Stock underlying the preferred stock retained by Mr. Lazar in a resale registration statement within 30 days of the transaction closing.
- Reason for Resignations: The resignations of the former directors and officers were not based on any disagreement with the Company regarding operations, policies, or practices.
Important Facts for Investor Verification
- Verify the filing of the joint Schedule 13D by the new investor group to confirm beneficial ownership percentages and voting agreements.
- Confirm the appointment of Junyi Dai as CEO and Chairman and review his background in real estate investment versus biopharmaceutical operations.
- Monitor the filing of the resale registration statement for the shares retained by David Lazar.
- Assess the impact of the new ownership structure (96.20% held by the new group) on future capital raising and strategic direction.
- Note that this filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for liquidity and burn rate information.